The three receptors it targets are: GLP-1 receptors : Help control appetite and slow digestion GIP receptors : Support insulin function and glucose regulation Glucagon receptors : Promote energy expenditure and fat burning This triple-action approach sets Retatrutide apart from current FDA-approved medications, such as semaglutide (found in Ozempic and Wegovy), which only target GLP-1 receptors, and tirzepatide (Mounjaro and Zepbound), which targets both GLP-1 and GIP receptors
There are different designations for compounding pharmacies: 503A and 503B
The Type 2 diabetes (T2D) market is composed of dozens of agents that span a multitude of classes (e.g., GLP-1, SGLT2, and DPP-4) and formulations (e.g., oral and injectable)
Without enough sleep, your body systems don't complete the necessary repairs, leading to cloudy thinking, poor concentration, low energy and mood swings